42 studies found for:    CT-011
Show Display Options
Download search resultsDownload the search results for:
CT-011 (42 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Active, not recruiting Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma
Condition: Lymphoma
Interventions: Drug: CT-011;   Drug: Rituximab
2 Completed Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
Conditions: Melanoma;   Malignant Melanoma
Intervention: Drug: CT-011
3 Completed Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone Administered Intravenously to Patients With Colorectal Adenocarcinoma Previously Untreated for Metastatic Disease
Condition: Metastatic Colorectal Cancer
Interventions: Drug: CT-011;   Drug: FOLFOX
4 Recruiting Gemcitabine and CT-011 for Resected Pancreatic Cancer
Conditions: Pancreatic Neoplasms;   Cancer of the Pancreas;   Neoplasms Pancreatic;   Pancreatic Cancer;   Pancreas Cancer
Interventions: Biological: CT-011;   Drug: Gemcitabine
5 Terminated Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection
Condition: Chronic Hepatitis C
Intervention: Drug: CT-011
6 Terminated Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma
Condition: Primary Hepatocellular Carcinoma
Intervention: Drug: CT-011
7 Recruiting Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: CT-011 (Anti-PD1 Antibody);   Other: Sipuleucel-T (Provenge);   Drug: Cyclophosphamide
8 Completed
Has Results
CT-011 MAb in DLBCL Patients Following ASCT
Conditions: Lymphoma, Large Cell, Diffuse;   Lymphoma, Mixed Cell, Diffuse;   Primary Mediastinal Large B-Cell Lymphoma
Intervention: Drug: CT-011
9 Active, not recruiting Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation
Condition: Multiple Myeloma
Interventions: Drug: CT-011;   Biological: Dendritic Cell Fusion Vaccine
10 Withdrawn CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors
Conditions: Breast Cancer;   Colon Cancer;   Pancreatic Cancer;   Sarcoma;   Ovarian Cancer
Interventions: Biological: p53: 264-272 peptide;   Drug: CT-011
11 Active, not recruiting PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine
Condition: Renal Cell Carcinoma
Interventions: Drug: CT-011;   Biological: DC/RCC fusion vaccine
12 Recruiting Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission
Conditions: Acute Myelogenous Leukemia;   AML
Interventions: Biological: DC AML Vaccine;   Drug: CT-011
13 Recruiting Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma and Relapsed Glioblastoma Multiforme
Condition: Malignant Gliomas
Intervention: Biological: CT-011
14 Recruiting Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: lenalidomide;   Biological: pidilizumab;   Other: pharmacological study;   Other: laboratory biomarker analysis
15 Suspended Duration of Effect of Alipogene Tiparvovec Treatment, Which Was Administered in Other Studies
Condition: Hyperlipoproteinemia Type I
Intervention:
16 Enrolling by invitation Study to Re-assess and Re-confirm Data Previously Recorded About the Incidence and Severity of Acute Abdominal "Pancreatitis" Episodes in Lipoprotein Lipase Deficient (LPLD) Subjects Previously Enrolled on AMT Clinical Studies
Condition: Lipoprotein Lipase Deficiency
Intervention:
17 Active, not recruiting A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.
Conditions: Advanced Solid Tumor;   Lymphomas
Intervention: Drug: LEE011
18 Unknown  Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase [S447X]
Condition: Familial Lipoprotein Lipase Deficiency
Interventions: Genetic: Alipogene Tiparvovec (AMT-011), Human LPL [S447X];   Drug: Mycophenolate mofetil;   Drug: cyclosporine
19 Completed Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects
Condition: Familial Lipoprotein Lipase Deficiency
Interventions: Genetic: Alipogene Tiparvovec (AMT-011), Human LPL [S447X];   Drug: mycophenolate mofetil;   Drug: cyclosporine;   Drug: methylprednisolone
20 Completed Adverse Reactions to MR and CT-examinations (Enhanced and Unenhanced)
Conditions: Renal Adverse Events - Contrast Induced Nephropathy (CIN);   Non-renal Adverse Events
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years